| Prev Close | 47.99 |
| Day Low/High | 47.26 / 48.75 |
| 52 Wk Low/High | 32.47 / 62.16 |
Agios Pharmaceuticals, Inc. (AGIO)
48.55
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 58.95B |
| Market Cap | 2.83B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
These 4 Healthcare Charts Are Signaling Buys
Here's a rundown of four technical setups that are showing solid trading potential.
Why Celgene Is a Core Biotech Holding
Celgene's days of stellar growth will continue to stretch far into the future.
Agios Shares Spike on Planned Drug Application
The drugmaker plans to submit the first targeted-blood-cancer drug to the U.S. by the end of the year.
Don't Buy Into This Kind of Bull
Risks far outweigh the possible rewards of buying into late bullishness.
Markers Spotted Point to a Top
At the very least, move those stop loss levels in very close on long positions.
2 'Rules of the Road' for Biotech Investing
Follow these maxims and you should do well in this volatile sector.
Jim Cramer Says Own Allergan, Disney, MasterCard, Starbucks
TheStreet's Jim Cramer answers viewers' questions on Allergan, Pfizer, Disney, MasterCard, Chipotle, Under Armour and more.
Stocks Low But Not Tempting
Picking up some high yielders might be worthwhile.
Biotech Stocks at a Crossroad
Own them, or take something off the table?
Here Are the 2 Best CEOs You Can Bank On
And they're both named Bob.
A Tasty Reversal With 6 Key Ingredients
But tomorrow we hear from the banks.
Momentum Is Not Dead
The chasing in certain areas was intense.
GMCR Starts to Look Interesting
I would continue to take any buy triggers in this one.
Go With What's Worked, Part 1
Throughout this historic run, four groups have consistently led the market.
A Study on Apple
Also on Agios Pharmaceuticals
Damage to Indices Was Fairly Minimal
But stay disciplined, honor your stops and protect gains.
It Doesn't Stop
The end-of-the-year phenomenon is working.
You Have to Love Biotech
In this era of turmoil, investors can take comfort in this sector.
Cramer: A Dozen Sectors to Snap Up
As 2014 winds down, you could almost throw darts at these standout groups -- but here are my own picks.
Here's Your Thesis to Buy
This market provides a slew of reasons to buy right now.
Volatility Smokescreen
Bet with common sense not against it.
